Valentina N. Nikolic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina N. Nikolic has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Aleksandra Ignjatović
Department of Medical Statistics and Informatics, University of Nis Faculty of Medicine, Nis, Serbia
1 shared publicationDejan Mitić
Department of Gynaecology and Obstetrics, University of Niš Faculty of Medicine, Niš, Serbia
1 shared publicationDragana Stokanovic
University of Nis Faculty of medicine
1 shared publication- Dragana Stokanovic
Dept. of Pharmacology and Toxicology Faculty of Medicine University of Niš Bul. Dr. Zorana Djindjica 81 18000 Niš Serbia
1 shared publication Dragana Stokanović
Department of Pharmacology with Toxicology, University of Niš Faculty of Medicine, Niš, Serbia
1 shared publicationHristina Trajković
Department of Pharmacology with Toxicology, University of Niš Faculty of Medicine, Niš, Serbia
1 shared publication
Latest Publications
- Open Access
- 13 April 2024
- Published by University of Nis in Facta Universitatis, Series: Medicine and Biology
POPULATION PHARMACOKINETICS OF PANTOPRAZOLE IN PATIENTS ON DUAL ANTIPLATELET THERAPY FOLLOWING ACUTE CORONARY SYNDROME
This study investigates factors influencing pantoprazole pharmacokinetics (PK) in patients with acute coronary syndrome (ACS) undergoing dual antiplatelet therapy (DAPT) comprising acetylsalicylic acid and clopidogrel, alongside concomitant pantoprazole to mitigate gastrointestinal risks. We conducted a prospective analysis on 93 ACS patients, assessing pantoprazole PK parameters and their correlation with C-reactive protein (CRP) levels, indicative of inflammation. Blood samples for pantoprazole concentration and CRP levels were collected according to a predefined schedule, post-oral pantoprazole administration at steady state. The study highlights a notable influence of CRP levels on pantoprazole clearance, underscoring inflammation’s impact on drug metabolism. Elevated CRP was associated with altered pantoprazole pharmacokinetics, suggesting that inflammatory status significantly contributes to metabolic variability in this patient population. Our findings suggest the need for personalized pantoprazole dosing in ACS patients on DAPT, considering the inflammatory status as reflected by CRP levels. This approach could optimize therapeutic efficacy and minimize adverse effects, advancing personalized treatment strategies in the management of ACS.
- 13 April 2024
- Published by University of Nis in Facta Universitatis, Series: Medicine and Biology
Open AccessPOPULATION PHARMACOKINETICS OF PANTOPRAZOLE IN PATIENTS ON DUAL ANTIPLATELET THERAPY FOLLOWING ACUTE CORONARY SYNDROME
This study investigates factors influencing pantoprazole pharmacokinetics (PK) in patients with acute coronary syndrome (ACS) undergoing dual antiplatelet therapy (DAPT) comprising acetylsalicylic acid and clopidogrel, alongside concomitant pantoprazole to mitigate gastrointestinal risks. We conducted a prospective analysis on 93 ACS patients, assessing pantoprazole PK parameters and their correlation with C-reactive protein (CRP) levels, indicative of inflammation. Blood samples for pantoprazole concentration and CRP levels were collected according to a predefined schedule, post-oral pantoprazole administration at steady state. The study highlights a notable influence of CRP levels on pantoprazole clearance, underscoring inflammation’s impact on drug metabolism. Elevated CRP was associated with altered pantoprazole pharmacokinetics, suggesting that inflammatory status significantly contributes to metabolic variability in this patient population. Our findings suggest the need for personalized pantoprazole dosing in ACS patients on DAPT, considering the inflammatory status as reflected by CRP levels. This approach could optimize therapeutic efficacy and minimize adverse effects, advancing personalized treatment strategies in the management of ACS.
- Open Access
- 1 April 2024
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 65 (2) , 138-145
Factors contributing to variability in metformin concentration in polycystic ovary syndrome
To investigate the factors affecting metformin concentrations after chronic administration in patients with polycystic ovary syndrome (PCOS), focusing on the pharmacokinetic variability and its implications for personalized therapy.This study enrolled ...
- 1 April 2024
- Published by Croatian Medical Journals in Croatian Medical Journal
- Vol. 65 (2) , 138-145
Open AccessFactors contributing to variability in metformin concentration in polycystic ovary syndrome
To investigate the factors affecting metformin concentrations after chronic administration in patients with polycystic ovary syndrome (PCOS), focusing on the pharmacokinetic variability and its implications for personalized therapy.This study enrolled ...
- Open Access
- 4 December 2023
- Published by Springer Nature in Research Square
Population Pharmacokinetics of Pantoprazole in Patients on Dual Antiplatelet Therapy following Acute Coronary Syndrome
Purpose Pantoprazole, a widely prescribed proton pump inhibitor, is still not fully characterized in terms of its pharmacokinetic (PK) properties. In this study, we employed nonlinear mixed-effects modeling to investigate factors influencing the variability in pantoprazole PK in patients with acute coronary syndrome undergoing dual antiplatelet therapy. Methods Blood samples were collected from 93 adult males and females receiving oral pantoprazole. Through a stepwise regression procedure various demographic and clinical covariates were tested in relation to pantoprazole concentration and elimination. These results were further substantiated by the reduction of point dispersion in goodness-of-fit plots, depicting the individual predicted versus measured concentrations, and through bootstrapping analysis. Results Pantoprazole clearance is notably influenced by C-reactive protein (CRP) levels and concurrent use of statins. Conclusion This discovery holds significant implications for tailoring pantoprazole treatment on an individual basis, providing valuable insights for optimizing therapeutic strategies in the management of patients with acute coronary syndrome, thereby maximizing therapeutic benefits.
- 4 December 2023
- Published by Springer Nature in Research Square
Open AccessPopulation Pharmacokinetics of Pantoprazole in Patients on Dual Antiplatelet Therapy following Acute Coronary Syndrome
Purpose Pantoprazole, a widely prescribed proton pump inhibitor, is still not fully characterized in terms of its pharmacokinetic (PK) properties. In this study, we employed nonlinear mixed-effects modeling to investigate factors influencing the variability in pantoprazole PK in patients with acute coronary syndrome undergoing dual antiplatelet therapy. Methods Blood samples were collected from 93 adult males and females receiving oral pantoprazole. Through a stepwise regression procedure various demographic and clinical covariates were tested in relation to pantoprazole concentration and elimination. These results were further substantiated by the reduction of point dispersion in goodness-of-fit plots, depicting the individual predicted versus measured concentrations, and through bootstrapping analysis. Results Pantoprazole clearance is notably influenced by C-reactive protein (CRP) levels and concurrent use of statins. Conclusion This discovery holds significant implications for tailoring pantoprazole treatment on an individual basis, providing valuable insights for optimizing therapeutic strategies in the management of patients with acute coronary syndrome, thereby maximizing therapeutic benefits.